New Delhi, April 12
A team of UK researchers has found the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups, including neonates, children, and pregnant women.
Sepsis, a life-threatening condition resulting from the immune system's overreaction to infection, remains a leading global cause of mortality, accounting for an estimated 11 million deaths annually.
Young children, especially those under five, and pregnant women are highly vulnerable due to immunological changes and increased susceptibility.
The study analysed serial blood samples from 252 patients (111 paediatric, 72 maternity, and 69 neonatal cases) with suspected sepsis.
The results showed that IL-6 consistently outperformed traditional biomarkers in distinguishing bacterial from non-bacterial infections.
"IL-6 also effectively stratified sepsis severity, distinguishing between mild infection, sepsis, and septic shock, a critical capability for guiding timely and appropriate treatment," the study showed.
The team explained how IL-6 has significant advantages over traditional biomarkers.
"IL-6 secretion rises within one to two hours, peaks at six hours, and decreases by 24 hours, whereas CRP and PCT peak much later at 48 and 24 hours, respectively. This faster, steeper response makes IL-6 a promising biomarker for earlier sepsis detection," said lead author Dr. Sean Whelan.
C-reactive protein (CRP) is a protein in the blood that indicates inflammation. PCT refers to Procalcitonin -- a biomarker for bacterial infections.
"Our findings reinforce the potential of IL-6 as a promising biomarker in sepsis diagnosis," Whelan said.
"With wider adoption and in combination with clinical assessment, IL-6 could significantly improve clinical decision-making and support timely, targeted treatment for high-risk patients," the expert added.
The study, presented at the annual Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Austria, is the first to evaluate IL-6's diagnostic performance in a real-world cohort across all three populations.
— IANS
Reader Comments
This is such important research! As a father who nearly lost my newborn to sepsis, earlier detection could be life-changing for so many families. The 1-2 hour response time is incredible compared to current methods. ðŸ‘
Interesting findings, but I wonder about implementation challenges. Many hospitals in developing countries still struggle with basic CRP testing. Will IL-6 testing be affordable and accessible where it's needed most?
The study sample size seems relatively small (252 patients). While promising, I'd like to see larger trials before widespread adoption. Still, this could be a game-changer for neonatal ICUs if validated.
As a pediatric nurse, I see sepsis cases weekly. The ability to distinguish severity levels (mild infection vs septic shock) would be SO valuable for treatment decisions. Hoping this gets fast-tracked for clinical use!
The 6-hour peak vs 24-48 hours for CRP/PCT could make all the difference in those critical early hours. Wonder if this could be adapted for rapid tests in emergency departments?
My sister survived sepsis after childbirth, but it was touch-and-go for days. So glad researchers are focusing on high-risk groups like pregnant women. Every minute counts with sepsis! â¤ï¸
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.